home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

638.88 -3.71 (-0.58%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

62 63 Next >

IBD's 100 Best ESG Companies For 2023 ↗

October 27, 2023

The companies on our list combine high sustainability scores and top stock ratings.

Via Investor's Business Daily

$100 Invested In This Stock 20 Years Ago Would Be Worth $6,000 Today ↗

October 19, 2023

Via Benzinga

Price Over Earnings Overview: Regeneron Pharmaceuticals ↗

October 17, 2023

Via Benzinga

The Latest Analyst Ratings for Regeneron Pharmaceuticals ↗

October 11, 2023

Via Benzinga

Down 45%, Is Intellia a Buy? ↗

October 10, 2023

Intellia's operating in the high-growth field of gene editing.

Via The Motley Fool

Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

October 26, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Announces Investor Conference Presentations

October 25, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Stock-Split Watch: Could These 2 Growth Stocks Be Next? ↗

October 25, 2023

Neither company has discussed it, at least not yet.

Via The Motley Fool

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END

Via FinancialNewsMedia

P/E Ratio Insights for Regeneron Pharmaceuticals ↗

October 06, 2023

Via Benzinga

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

October 22, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

October 21, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Which Is the Better Long-Term Hold for Investors: Pfizer or Roche? ↗

October 21, 2023

The venerable pharmaceutical companies' shares have slumped this year.

Via The Motley Fool

Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

October 20, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗

October 04, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 18, 2023

Via Benzinga

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing ↗

October 18, 2023

The company can begin a pivotal study of its treatment for cardiomyopathy.

Via Investor's Business Daily

Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN

October 18, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

October 18, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) Deserves Consideration as a Quality Investment. ↗

October 17, 2023

This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN)

Via Chartmill

Healthcare Portfolio Focus Stocks ↗

October 16, 2023

The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields.

Via Talk Markets

Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know ↗

October 16, 2023

Via Benzinga

2 Healthcare Stocks Near 52-Week Highs Still Worth Buying ↗

October 16, 2023

These two large-cap biopharma companies could have more room to run.

Via The Motley Fool

Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

October 15, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points ↗

October 14, 2023

Broadcom and Arista lead five stocks sporting a flat base.

Via Investor's Business Daily

Topics Artificial Intelligence

Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up ↗

October 09, 2023

Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment.

Via Talk Markets

Biotech Sector: On The Verge Of Triumph Or Turmoil? ↗

October 06, 2023

In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.

Via Talk Markets

EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA

October 05, 2023

First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

This Market-Beating Stock Just Gave Investors More Reasons to Invest ↗

October 05, 2023

There is a lot going the way of this biotech giant right now.

Via The Motley Fool

Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close) ↗

October 05, 2023

This stock puts the "big" in big pharma after massive gains in recent years.

Via The Motley Fool

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

62 63 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com